Zentalis Pharmaceuticals, Inc. (ZNTL) Stock Grade

About Zentalis Pharmaceuticals, Inc.'s fundamentals

Zentalis Pharmaceuticals is a small-cap biotechnology company with a market capitalization of $97.0 million that reported a net loss in its latest annual statement, resulting in a net margin of 0.0% and making traditional profitability metrics like P/E ratio and return on equity unavailable. The company experienced a -100.0% year-over-year revenue decline, indicating either a significant contraction in commercial operations or a transition period in its business model. As a pre-profit or early-stage biotech company, Zentalis does not pay a dividend, which is typical for firms focused on research and development rather than returning capital to shareholders.